BioMarin Pharmaceutical Inc (BMRN) Stock Analysis
Verdict: HOLD
Voxzogo's achondroplasia expansion and $725M FCF balance pipeline setbacks and past EPS misses, supporting moderate upside.
Investment score: 61/100
Analysis as of
7-factor investment score
- Valuation: 52/100 (weight 20%)
- Financial Health: 78/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 38/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
BioMarin Pharmaceutical Inc opportunities and risks
What speaks for BMRN
- Voxzogo achondroplasia expansion accelerates core revenue past $3.2B
What speaks against BMRN
- Pipeline rationalization reduces future TAM expansion catalysts
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BMRN | 173.2x | 3.7x | 41.6x | 75.5% | 2.1% | 5.8% |
| NBIX | 21.4x | 4.5x | 16.6x | 98.0% | 20.9% | 5.7% |
| EXEL | 17.6x | 6.0x | 13.9x | 96.5% | 35.3% | 7.9% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
| BBIO | n/a | 19.5x | n/a | 93.1% | -100.6% | -4.4% |
| HALO | 30.8x | 7.7x | 20.8x | 78.2% | 24.9% | 6.3% |
| Peer median | 17.6x | 6.0x | 13.9x | 93.1% | 20.9% | 5.7% |
Frequently asked questions about BioMarin Pharmaceutical Inc (BMRN)
Is BMRN stock a good investment?
The TradeMates model rates BioMarin Pharmaceutical Inc as HOLD with an investment score of 61/100. Voxzogo's achondroplasia expansion and $725M FCF balance pipeline setbacks and past EPS misses, supporting moderate upside. This is algorithmic model output, not personal investment advice.
Is BMRN stock a buy?
The TradeMates model verdict for BMRN is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.